Interactive Session:
28. Challenging HIV Cases
Thursday, October 8, 2015: 10:30 AM-12:00 PM
Room: 20--ABCD

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • identify complicating variables in HIV cases
  • apply strategies to address treatment complications
  • describe alternate treatment strategies for management of HIV

Target Audience: Public health practitioners, Members-in-training, Infectious diseases physicians, Infectious diseases pediatricians, HIV specialists, HIV clinicians, Clinicians, Academicians

Tracks: Trainee, HIV-STD-TB, Adult ID

Interactive Moderators:  Pablo Tebas, MD, FIDSA, University of Pennsylvania , Joel Gallant, MD, MPH, FIDSA, Southwest CARE Center and Nesli Basgoz, MD, FIDSA, Massachusetts General Hospital

Interactive Panelists:  Judith Currier, MD, MSc, FIDSA, UCLA , Wendy Armstrong, MD, FIDSA, Emory University and Renslow Sherer, MD, University of Chicago Hospitals

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 CreditTM

ACPE Credits: ACPE 1.5 application-based contact hours (0.15 CEU) of pharmacy CE

ACPE Number: 0221-9999-15-154-L02-P

Disclosures:

P. Tebas, Merck: Consultant , Consulting fee
Glaxo: Consultant , Consulting fee

J. Gallant, AbbVie: Investigator , Research support
Bristol-Myers Squibb: Investigator and Scientific Advisor , Consulting fee and Research support
Gilead Sciences: Investigator and Scientific Advisor , Consulting fee and Research support
Janssen Therapeutics: Investigator and Scientific Advisor , Consulting fee and Research support
Merck & Co.: Investigator and Scientific Advisor , Consulting fee and Research support
Sangamo BioSciences: Investigator , Research support
ViiV Healthcare: Investigator and Scientific Advisor , Consulting fee and Research support

N. Basgoz, None

J. Currier, None

W. Armstrong, None

R. Sherer, Gilead: Scientific Advisor , Consulting fee
Janssen: Independent Contractor , Educational grant

See more of: Interactive Session

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.